Trials / Unknown
UnknownNCT04890366
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimethyl Fumarate | Dimethyl fumarate 240mg orally twice daily for 3 consecutive days |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2021-05-18
- Last updated
- 2022-06-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04890366. Inclusion in this directory is not an endorsement.